Bhattacharya IS, et al. - In this substudy of phase III randomized controlled trial (IMPORT LOW), researchers focused on patient-reported outcomes over 5 years after partial-breast and reduced-dose radiotherapy vs whole-breast radiotherapy in women with low-risk breast cancer after breast-conserving surgery. IMPORT LOW demonstrated noninferiority of the former vs the latter for local relapse and similar or reduced toxicity at 5 years. Randomly, patients were treated with 40 Gy whole-breast radiotherapy (control), 36 Gy whole-breast and 40 Gy partial-breast radiotherapy (reduced-dose), or 40 Gy partial-breast radiotherapy only (partial-breast) in 15 fractions. Findings revealed attenuation of most adverse effects (AEs) over time, with fewer AEs observed in the partial-breast and reduced-dose groups. Baseline predictors of AE reporting were younger age, larger breast size/surgical deficit, lymph node positivity, and higher levels of anxiety/depression. Over time, attenuation in the prevalence of breast hardness, pain, oversensitivity, edema, and skin changes, whereas an increase in breast shrinkage was noted.